Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Recruiting · NCT02174549 · Registry updated 2026-04-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | Digestive System Diseases, Digestive System Neoplasms, Hypoxia, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Respiratory, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-04-20 | NCT02174549 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Teclison Ltd. | 3 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Stanford University | Palo Alto | United States | 51 |
| University of Pennsylvania | Philadelphia | United States | 507 |